Patients who undergo splenectomy and recipients of allogeneic marrow (alloBMT) or peripheral stem cell transplantation are at increased risk of overwhelming infection from encapsulated organisms such as Streptococcus pneumoniae, Haemophilus influenzae and Neiserria meningitidis. As prophylaxis against these pathogens splenectomised patients are immunised and may also receive antibiotics for life. We report relapsing overwhelming sepsis caused by penicillin-resistant pneumococcus in a patient who was immunised and received prophylactic phenoxymethylpenicillin for 8 months following splenectomy and matched unrelated donor (MUD) marrow transplantation for refractory T cell lymphoma. No obvious focus of sepsis was found during any of the three episodes and S. pneumoniae serogroup 6, subtype 6B was isolated from blood cultures on each occasion. He was treated with i.v. cephalosporins, as the organisms were resistant to penicillin with a minimum inhibitory concentration (MIC) of 2.0, and there was complete resolution of symptoms each time. In the light of recurrent sepsis with this penicillin-resistant organism the decision was made to give prophylactic levofloxacin for the next 12 months. This case illustrates that the choice of prophylactic regimen and the treatment of sepsis in immunocompromised patients remain difficult and challenging issues. 5 They are also immunised with 23-valent polysaccharide pneumococcal vaccine but the ability to generate an adequate antigen-specific immune response in recipients of alloBMT is time-dependent and may not be consistent. 6, 7 To highlight the challenges in the primary prevention of sepsis with encapsulated bacteria in this group of patients, we report on the recurrence of serious penicillin-resistant pneumococcal sepsis in a patient, 8 months post-MUD transplantation for refractory T cell lymphoma.
fulminant sepsis in such patients is usually due to encapsulated bacteria such as Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae. Patients undergoing splenectomy and/or alloBMT are offered prophylactic penicillin or amoxycillin for life, 4 but this practice is still controversial and may result in the emergence of antibiotic-resistant strains. 5 They are also immunised with 23-valent polysaccharide pneumococcal vaccine but the ability to generate an adequate antigen-specific immune response in recipients of alloBMT is time-dependent and may not be consistent. 6, 7 To highlight the challenges in the primary prevention of sepsis with encapsulated bacteria in this group of patients, we report on the recurrence of serious penicillin-resistant pneumococcal sepsis in a patient, 8 months post-MUD transplantation for refractory T cell lymphoma.
Case report
A 27-year-old man presented with splenomegaly and pancytopenia. A diagnosis of T cell NHL was made on trephine biopsy. He was treated with nine courses of CHOP chemotherapy. A splenectomy was performed 5 months after the initial diagnosis and nodular collections of small lymphocytic cells with slightly irregular nuclei and low mitotic rate, were detected on splenic sections. The cells expressed CD3, CD5 and CD43, thus confirming a diagnosis of lowgrade peripheral T cell lymphoma. Prior to the splenectomy he was immunised with 23-polyvalent polysaccharide pneumococcal vaccine, H. influenza type b (Hib) conjugate vaccine and meningococcal type A and C polysaccharide vaccine. He was subsequently treated with more chemotherapy (miniBEAM and subsequently a combination of idarubicin and cytosine arabinoside). However, marrow examination after completing chemotherapy continued to show infiltration with lymphoma, indicating refractory disease.
Since the patient's sister was not HLA compatible, matched unrelated donor transplantation was performed 17 months after the initial diagnosis. The pretransplant conditioning regimen consisted of fractionated total body irradiation 1440 cGy and cyclophosphamide (120 mg/kg). Graft-versus-host disease (GVHD) prophylaxis consisted of
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Campath (10 mg/day from day Ϫ5 to day Ϫ1), cyclosporin A and short-course methotrexate. There were no major immediate post-transplant complications. On day ϩ26, cytomegalovirus (CMV) polymerase chain reaction (PCR) analysis was positive in the blood and he was treated with full-dose intravenous ganciclovir (5 mg/kg twice daily) for 4 weeks until CMV PCR was negative, and then daily for a further 3 weeks. Prophylactic antibiotics on discharge included phenoxymethylpenicillin 250 mg twice a day and cotrimoxazole. A CT scan of chest, abdomen and pelvis, and trephine biopsy performed at this stage were essentially normal, although a non-clonal increase in T cells was observed on the trephine. Full donor chimerism was established by mini-satellite probe analysis.
On day ϩ107, CMV PCR analysis was again positive in blood and a chest X-ray showed shadowing in the right mid-zone. There was pronounced lymphocytosis in peripheral blood (between 6 and 8 ϫ 10 9 /l), with a predominance of reactive CD8-positive cells. A mild lymphocytic infiltrate was evident on transbronchial biopsy and CMV PCR on brochioıalveolar lavage was positive. He received 3 weeks of full-dose ganciclovir, following which CMV PCR was negative. He continued on once daily intravenous ganciclovir for 2. weeks and then oral ganciclovir (1 g three times a day) for 5 weeks. Peripheral blood, however, continued to show lymphocytosis, with marked elevation of CD8-positive cells. TCR gene rearrangement was negative on Southern blot analysis.
Eight months post transplant, the patient presented with high-grade fever and dry cough. Chest X-ray showed haziness in the right upper zone. However, a high-resolution CT scan of lungs was normal and CMV PCR analysis of blood was negative. S. pneumoniae was isolated from blood cultures. It was resistant to penicillin and erythromycin, but sensitive to cefotaxime, rifampicin and vancomycin. There was a marked clinical improvement after 7 days of cefotaxime, and he received a further 10-day course of once-daily intravenous ceftriaxone, as an outpatient, following which he re-commenced prophylactic oral penicillin at a higher dose of 500 mg twice a day, to cover the possibility of lowlevel resistance. Within a week of completing treatment with ceftriaxone, he re-presented with high-grade fever, dyspnoea, cough and hypotension. The same strain of S. pneumoniae with antibiotic sensitivity observed during the previous admission was once again isolated from blood cultures (see Table 1 ). CT scan of the abdomen revealed thickening of retro-peritoneal fascial planes with some peri-colic free fluid. These changes were non-specific and thought to be consistent with inflammation. X-ray of paranasal sinuses was normal. He was treated with cefotaxime for 2 weeks and then discharged on oral prophylactic penicillin 500 mg twice a day. However, within 2 days, he was admitted again with high-grade fever, dyspnoea and hypotension, and the same strain of S. pneumoniae that was resistant to penicillin was once again isolated from blood cultures. A repeat CT scan of the abdomen showed resolution of the changes seen on the previous abdominal scan. A white cell scan revealed no localised focus of uptake. He was treated with intravenous cefotaxime for 7 days, together with rifampicin for 14 days and levofloxacin at a dose of 1 g/day for 14 days. He made a full recovery once again. We propose to continue levofloxacin at a dose of 500 mg/day for 1 year at which time his prophylaxis will be reviewed.
Discussion
Pneumococcal bacteraemia is the most common cause of serious or fulminant sepsis in splenectomised individuals and mortality remains high with rates ranging from 15 to 60% in different patient groups. 8 Patients receiving chemotherapy, radiotherapy or both are at greatest risk of serious infections after splenectomy. 9 Although sepsis due to penicillin-resistant strains is considered to be rare in splenectomised patients, 10 the rate is increasing. 11 If the rate at which resistance has progressed is maintained, the morbidity and mortality as a result of resistant pneumococcal infections is likely to increase significantly. 12 Owing to the resistant nature of the S. pneumoniae isolated from our patient and the failure of penicillin prophylaxis a novel prophylactic antibiotic regimen had to be considered. Of the agents that could be used for treatment few are suitable to be taken long term as prophylaxis either because of potential side-effects or because of the emergence of resistance if given as monotherapy (eg rifampicin). It has been suggested that prophylactic quinolones can reduce the incidence of Gram-negative bacteraemia in neutropenic patients 13 but they are rarely recommended for treatment of pneumococcal infections due to their marginal activity against some Gram-positive bacteria. Levofloxacin is a quinolone recently licensed in the UK. It has improved activity against Gram-positive organisms [14] [15] [16] [17] and a long half-life allowing once daily dosing. Newer quinolones are currently in development that will have enhanced Gram-positive activity so the range of such options may increase.
Recent reports on the emergence of vancomycin tolerance in S. pneumoniae 18 have re-emphasised the need for alternative strategies for primary prevention of pneumococcal infections in alloBMT and asplenic patients. While the mainstay of 'non-antibiotic' prophylaxis is immunisation, the use of the polyvalent pneumococcal vaccine is not without drawbacks. Studies by Winston et al 6 suggested that antibody responses to the vaccine are poor if patients are immunised early-on post transplantation, and if they receive steroids for treatment of GVHD. These observations are supported by data from children, which suggest that the period between immunisation and transplantation could be a major determinant of the ability of the immune system to react to the presence of pneumococcal antigens during immunisation. 7 S. pneumoniae serotype 6B, the organism isolated from our patient on each occasion, is one of six serotypes (6B, 10A, 18C, 19F, 22F, and 23F) found in the 23-valent polysaccharide vaccine that have been found to be less immunogenic than others. 19 This may be another factor contributing to his poor response.
In addition, the ability of the recipient to initiate and maintain an adequate immune response needs to be monitored in alloBMT recipients, and repeat doses of the vaccine may be required at 2-3 year intervals. Measurement of functional pneumococcal antibodies may help to identify non-responders who may require treatment with immunoglobulin. 20 Although splenic autotransplantation may facilitate an adequate immune response in patients who are splenectomised as a result of trauma, 21 this is clearly not an option in our patient.
The use of mucosal vaccination for prophylaxis against pneumococcal infections in mice has yielded encouraging results; 22 it remains to be determined whether adequate protection by mucosal vaccines can be provided in asplenic patients. There is also a conjugate pneumococcal vaccine undergoing trials currently that may provide hope of a more effective preventative regimen in future.
As has been shown, prophylaxis will not prevent all cases of sepsis in asplenic or transplanted individuals. 23 The key to this patient's survival was early presentation for appropriate intravenous therapy. In this country the incidence of cephalosporin resistance is low and cefotaxime in combination with rifampicin or vancomycin remains the treatment of choice for sepsis caused by penicillin-resistant pneumococcus. 4, 19 
